Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon beta-1a users

Plain language summaryA large retrospective study was carried out on people with multiple sclerosis (PwMS) being treated with intramuscular interferon-beta medication from the New York State Multiple Sclerosis Consortium. The aim of the study was to look at whether patient-reported and clinical measures could be used early on to predict whether PwMS have worsening of their disease. The study demonstrated that patient-reported levels of limitations in multiple physical and mental symptoms can predict future worsening in objectively quantified disability in PwMS who take intramuscular interferon-beta medication. Reported limitations in lower extremities and fatigue were the most predictive of future disability worsening. Tweetable abstractPatient-reported outcomes related to physical limitations predict future disability progression in people with multiple sclerosis. Introduction: Patient-reported outcomes (PROs) are valuable measures for routine clinical care of people with multiple sclerosis (pwMS). Materials: 646 pwMS treated with interferon-beta-1a (IFN-beta-1a) were retrospectively included from the New York State Multiple Sclerosis Consortium. Clinical and PRO data at enrollment and 3 year follow-up were collected. PwMS with stable disease and disability worsening were matched (1:1) based on age, Expanded Disability Status Scale (EDSS) scores and disease duration. Disability worsening was determined based on trial criteria. Results: PwMS with future EDSS worsening had higher baseline and follow-up timed-25-foot walk (6.6 vs 5.5 s; 9.1 vs 5.5 s; p < .001) when compared with stable pwMS. Worsening pwMS reported higher baseline difficulties in getting up (odds ratio [OR] = 2.4; p = 0.009), climbing stairs (OR = 1.6; p = 0.024) and standing (OR = 2.2; p < 0.001). Worsening pwMS reported greater lower limb limitations (OR = 2.3; p = 0.004) and fatigue (OR = 1.8; p = 0.002). Conclusion: Higher fatigue and lower limb functional limitations are significant predictors of future disability worsening in pwMS.

Automated summary

A large retrospective study found that patient-reported limitations in physical and mental symptoms can predict future disability worsening in multiple sclerosis (MS) patients treated with intramuscular interferon-beta medication. The study also identified lower extremities limitations and fatigue as the most predictive factors for disability worsening.